Meeting
2023 ASCO Annual Meeting
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).
Authors
David Paul Carbone
The Ohio State University Comprehensive Cancer Center, Columbus, OH
David Paul Carbone , Tudor-Eliade Ciuleanu , Michael Schenker , Manuel Cobo-Dols , Stephanie Bordenave , Oscar Juan-Vidal , Juliana Janoski De Menezes , Niels Reinmuth , Eduardo Richardet , Ying Cheng , Hideaki Mizutani , Luis G. Paz-Ares , Shun Lu , Tom John , Xiaoqing Zhang , Nan Hu , David Balli , Vipul Baxi , Jaclyn Neely , Martin Reck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03215706
Citation
J Clin Oncol 41, 2023 (suppl 17; abstr LBA9023)
DOI
10.1200/JCO.2023.41.17_suppl.LBA9023
Abstract #
LBA9023
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2024 ASCO Annual Meeting
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
First Author: Martin Reck
Poster
2023 ASCO Annual Meeting
A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.
First Author: Antonio Tito Fojo
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck